A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal by Faggiano, A et al.
A Decrease of Calcitonin Serum Concentrations Less
Than 50 Percent 30 Minutes after Thyroid Surgery
Suggests Incomplete C-Cell Tumor Tissue Removal
A. Faggiano, F. Milone, V. Ramundo, M. G. Chiofalo, I. Ventre, R. Giannattasio,
R. Severino, G. Lombardi, A. Colao, and L. Pezzullo
Istituto di Ricovero e Cura a Carattere Scientifico Fondazione SDN (A.F.), and Nuclear Medicine Unit
(R.G.), Azienda Sanitaria Locale Napoli 1 Centro, 80143 Napoli, Italy; Department of Molecular and
Clinical Endocrinology and Oncology (F.M., V.R., R.S., G.L., A.C.), Federico II University, and Surgery Unit
(M.G.C., L.P.), National Cancer Institute, Fondazione G. Pascale, 80131 Napoli, Italy; and Endocrinology
Unit (I.V.), G. Rummo Hospital, 80121 Benevento, Italy
Context and Objectives: The prognosis of medullary thyroid carcinoma (MTC) depends on the
completeness of the first surgical treatment. Todate, it is notpossible topredictwhether the tumor
has been completely removed after surgery. The aim of this studywas to evaluate the reliability of
an intraoperative calcitoninmonitoringasapredictorof the finaloutcomeafter surgery inpatients
with MTC.
Patients and Methods: Twenty patients underwent total thyroidectomy and central lymph node
dissection on the basis of a positive pentagastrin test. In six cases a preoperative diagnosis of MTC
was achieved at the cytological examination. During the surgical intervention, calcitonin was
measured at the time of anesthesia, at the time of manipulation, and 10 and 30 min after surgical
excision. At the histological examination, 10 patients had MTC and 10 had C cell hyperplasia.
Results:As comparedwith calcitonin levels before thyroidectomy, a decrease of calcitonin greater
than 50% 30min after surgery was able to significantly distinguish patients whowere cured from
those who experienced persistence of disease. It was not possible to find a similar result when the
decrease of calcitonin 10 min after surgery was considered.
Conclusions: A rate of calcitonin decrease less than 50% 30 min after thyroidectomy plus central
neck lymph node dissection suggests the persistence of tumor tissue in patients operated forMTC.
These results indicate that intraoperative calcitoninmonitoringmay be a useful tool to predict the
completeness of surgery in patients with MTC. (J Clin Endocrinol Metab 95: 0000–0000, 2010)
Medullary thyroid carcinoma (MTC) originates fromthe parafollicular cells (C cells) of the thyroid.
These cells produce calcitonin, which is a highly sensitive
and specific marker of MTC for both diagnosis and fol-
low-up (1, 2). The definitive cure of the tumor is strongly
dependent on the completeness of the first surgical treat-
ment (3). If total thyroidectomy and central neck lymph
node dissection are performed in all cases of MTC, it is a
matter of debate whether to perform lateral lymph node
dissection in any case or to limit this radical approach only
to patients with metastases in the central neck compart-
ment or palpable lateral neck lymph nodes (4–8). For this
purpose, it shouldbe considered that the riskofmetastases
in the contralateral neck compartment and the mediasti-
numdepends on the size of the primary tumor, the number
of central lymph node metastases, and tumor multicen-
tricity (8–10). If the first surgical treatment is so crucial for
the final outcome of the patient, on the other hand, there
are no clear criteria that can indicate to the surgeon
whether the tumor has been completely removed after to-
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tal thyroidectomy plus central lymph node dissection. In a
recent study evaluating the usefulness of intraoperative
pentagastrin (PG) test in predicting lymph node involve-
ment in patients withMTCwho underwent total thyroid-
ectomy plus central lymph node dissection, 80% of sub-
jects were correctly recognized to have postoperative
tumor remnants, and this procedure failed to detect tumor
remnant in 20% of uncured subjects (11). In the present
study, intraoperative calcitonin monitoring was per-
formed in patients whowere recommended for surgery on
the basis of the detection of high basal and PG-stimulated
calcitonin levels consistent with a diagnosis of MTC to
evaluate the reliability of this intraoperative procedure in
predicting the completeness of surgery.
Patients and Methods
Patients
Twenty consecutive patients (ninemales and11 females, aged
25–70 yr, range 50 2.3 yr), candidates for thyroid surgery on
the basis of abnormally increased calcitonin levels and without
preoperative evidence of lymph node or distantmetastases, were
enrolled in the study. All patients underwent thyroid surgery on
the basis of basal or PG calcitonin concentrations above 100
ng/liter (12). Five patients had basal serum calcitonin concen-
trations greater than100ng/liter, and15other patients hadbasal
calcitonin concentrations between 18 and 68 ng/liter and PG-
stimulated calcitonin concentrations greater than 100 ng/liter.
All patients had thyroid nodules at ultrasonography (US): eight
patients had a single nodule and 12 patients had two or more
nodules. None of the patients had positive lymph nodes on pre-
operative US.
A fine-needle aspiration biopsy was performed under US
guidance in all patients on the thyroid nodules with US features
suspicious for malignancy (absence of halo sign, microcalcifica-
tions. and hypoechogenicity) (13) or, in absence of this condi-
tion, on the largest nodule: a preoperative diagnosis ofMTCwas
obtained at fine-needle aspiration biopsy in six of 20 patients.
None of the patients was positive at the genetic analysis ofRET.
The surgical procedure for all of the patients consisted in total
thyroidectomy and central compartment lymph node dissection.
The latter consisted in the removal of the contents of the pretra-
cheal and paratracheal compartments bilaterally. Because none
of the patients had lymphnodemetastases at the preoperativeUS
examination or at the intraoperative surgical exploration, a rad-
ical neck dissection, including both central and bilateral neck
lymph node dissection, was not performed in any patient.
At the histological examination, MTC was found in 10 pa-
tients and C cell hyperplasia (CCH) only in 10 other patients
(Table 1). All patients gave written informed consent. The study
was conducted in accordance with the Declaration of Helsinki,
adhering to all local regulatory guidelines.
Outcome
After surgery, calcitoninwasmeasuredevery3monthsduring
the first year and then every 6 months; a PG test was performed
6 months after surgery in those patients with a histological di-
agnosis of MTC. A color-Doppler US was performed every 6
months in all patients. The mean follow-up time after surgery
was 14.6  1.7 months (range 6–30 months). There was no
evidence of disease persistence or relapse in 16 of the 20 patients.
Disease persistence was found in four patients, two of themwith
both basal and PG-stimulated abnormally high calcitonin levels
and two other patients with basal calcitonin levels 5 ng/liter or
less but a progressive increase of calcitonin during the follow-up
and positive PG-stimulated calcitonin response. These patients
underwent a careful radiological work-up andwere followed up
periodically with color Doppler US, contrast-enhanced com-
puted tomography and magnetic resonance imaging scan, and
18F-deoxy-D-glucose-positron emission tomography. One of the
four patients with persistent disease after surgery had US evi-
dence of tumor remnant in neck lymph node, which was con-
firmed at the 18F-deoxy-D-glucose-positron emission tomogra-
phy scan. This patient underwent a second surgery to remove
bilateral neck lymph nodes. The other three patients with post-
operative positive calcitonin did not show radiological signs of
tumorat the last radiological examinationperformed12,16, and
22 months after surgery, respectively.
Calcitonin assay
Serum calcitonin concentrations were determined by a com-
mercially available two-site sandwich-type chemiluminescent
immunometric assay (DiaSorin Inc., Stillwater, MN). Normal
values were 0.4–18.9 ng/liter for males and 0.0–5.5 ng/liter for
females. Analytic sensitivity was 1 ng/liter or less. The intra- and
interassay coefficients of variation were 3 and 4%, respectively,
at 70.4 ng/liter and 1 and 2%, respectively, at 179 ng/liter. No
hook effect was observed until a calcitonin concentration of
500,000 ng/liter. The calcitonin assay run time was 15 min.
PG  calcium test was performed as follows: calcium was
injected first, iv in 1 min at a dose of 2 mg/kg. PG was injected
in 15 sec at a dose of 0.5 g/kg in 5 ml of NaCl solution 0.9%.
TABLE 1. Patient characteristics
n Age/sex
Basal calcitonin
(ng/liter)
before surgery Histology
Tumor
stage
1 50/Female 68 MTC T1aN0
2 42/Female 198 MTC T1aN0
3 49/Female 42 MTC T1aN0
4 70/Female 465 MTC T2aN1
5 37/Male 29 CCH NA
6 58/Female 240 MTC T1aN0
7 25/Male 20 CCH NA
8 57/Male 55 CCH NA
9 48/Male 108 MTC T2aN1
10 32/Female 20 CCH NA
11 59/Male 23 CCH NA
12 47/Male 25 CCH NA
13 55/Male 18 CCH NA
14 58/Female 107 MTC T1aN0
15 45/Male 31 CCH NA
16 56/Male 45 MTC T2aN0
17 49/Female 56 MTC T2aN0
18 51/Female 28 CCH NA
19 54/Female 67 MTC T1aN0
20 59/Female 32 CCH NA
NA, Not applicable.
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Blood sampleswere collected at 0, 1, 2, 3, 5, and 10min after the
injection. According to Costante et al. (12), calcitonin peak
after a PG test greater than 100 pg/ml was considered indic-
ative for MTC.
The intraoperative calcitoninmonitoring procedure included
a first calcitonin measurement at the time of anesthesia (prein-
cision value); the following steps were measurement at the time
of manipulation (manipulation value), 10 min after surgical ex-
cision and 30 min after surgical excision. It was considered the
percent reduction from the highest preexcision value, using the
highest value between the preincision or themanipulation value.
Blood sampling site was an antecubital vein.
Statistical analysis
The statistical analysis was performed by SPSS for Windows
version 10 (SPSS, Inc., Chicago, IL). Data were expressed as
mean  SEM. The significance was defined as P  0.05. The
percent calcitonin decrease after the surgical intervention was
analyzed by receiver operator characteristic analysis by using a
non parametric model to determine the best cutoff to distinguish
patients cured and uncured by surgery.
Results
At the histological examination, 10 patients were affected
with MTC and 10 patients with CCH. Among patients
with MTC, tumor stage was T1N0 in six, T2N0 in two,
and T2N1 in two (Table 1). In the whole population, pre-
excision values of serum calcitonin were 908  695 ng/
liter (range 11–9160 ng/liter) and postexcision values
were 319  202 ng/liter (range 9–2845 ng/liter) 10 min
after the surgical excision and 146  75 ng/liter (range
7–1065 ng/liter) 30 min after the surgical excision. The
mean percentage decrease was 44 4.6% (range 13–76%)
10minaftersurgeryand612.9%(range39–80%)30min
after surgery (Table 2 and Fig. 1).
At the receiver operator characteristic analysis, a de-
crease of calcitonin serum concentrations greater than
50% 30 min after surgery was able to significantly distin-
guishbetweenpatientswhowere cured and thosewhohad
FIG. 1. Percent calcitonin decrease 10 and 30 min after surgery.
FIG. 2. Correlation between tumor outcome and percent calcitonin
decrease 30 min after surgery.
TABLE 2. Calcitonin decrease and outcome after surgery
n Age/Sex
Calcitonin reduction
10 min after
tumor removal (%)
Calcitonin reduction
30 min after
tumor removal (%) Outcome
Follow-up
(months)
Calcitonin levels
(ng/liter) at the
last follow-up time
1 50/Female 71 72 Remission 26 2
2 42/Female 15 63 Remission 18 2
3 49/Female 35 61 Remission 6 5
4 70/Female 69 16 Persistence 24 380
5 37/Male 58 67 Remission 12 5
6 58/Female 74 79 Remission 8 12
7 25/Male 70 65 Remission 6 4
8 57/Male 25 55 Remission 10 2
9 48/Male 56 39 Persistence 16 285
10 32/Female 13 56 Remission 12 2
11 59/Male 76 80 Remission 6 5
12 47/Male 36 55 Remission 8 2
13 55/Male 54 77 Remission 6 2
14 58/Female 21 56 Remission 30 2
15 45/Male 28 69 Remission 18 9
16 56/Male 30 40 Persistence 19 194
17 49/Female 29 44 Persistence 9 155
18 51/Female 41 71 Remission 16 5
19 54/Female 45 77 Remission 22 2
20 59/Female 33 59 Remission 21 2
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disease persistence during the follow-up with 100% sen-
sitivity and specificity (P  0.05) (Fig. 2). No statistical
significance was found to predict the patient outcome
when considering calcitonin serum concentrations 10min
after surgery.
An intraoperative calcitonindecrease greater than50%
30 min after the surgical resection was achieved in all the
16 patients who had complete remission during the fol-
low-up (662.4%),whereas the calcitonin decrease after
30 min was 16, 39, 40, and 44%, respectively, in the four
patients who had persistent disease after surgery (Fig. 2).
Discussion
The prognosis of a patient suffering fromMTC is strongly
related to the completeness of the first surgical interven-
tion. If tumor tissue is not totally removed, the subsequent
surgery is not as effective as a complete primary surgery in
achieving the disease remission (14).
Although preoperative calcitonin concentrations have
been reported to predict calcitonin normalization after
surgery (12), no clinical or biological parameters clearly
predict the postoperative outcome of MTC patients.
The main message of this study is that the intraopera-
tive calcitonin monitoring seems to represent a reliable
procedure todetermine, at the timeof surgery,whether the
patient can be considered free of disease after a conserva-
tive surgery limited to total thyroidectomy and central
compartment lymph node dissection. In the presence of a
calcitonindecrease greater than50%30minafter surgery,
tumor removal can be considered complete. On the other
hand, a calcitonin decrease less than 50% 30 min after
surgery indicates an incomplete tumor removal and sug-
gests to the surgeon to extend the operation on other
lymph node compartments. In their study, Scheuba et al.
(11) tried to validate a similar procedure, measuring the
response to intraoperative PG test to predict lateral lymph
node involvement and, consequently, whether to extend
surgery to other lymph node compartments after central
dissection. Although both the study by Scheuba et al. and
our study used a chemiluminescent method for calcitonin
measurement, a comparison between these two studies is
not completely feasible due to a different interassay coef-
ficient of variation.Apart from these technical aspects, the
intraoperative calcitonin monitoring seems to be more
cost effective than the intraoperative PG test in recogniz-
ing patients with incomplete surgery. The main difference
is that the sensitivity and negative predictive value of the
intraoperative calcitonin monitoring was 100% without
any false-negative result, whereas the sensitivity of intra-
operative PG test was 80% and negative predictive value
91% (11). This means that the latter procedure did not
recognize 20%ofpatientswhohadpersistent disease after
surgery. A second relevant aspect is that the PG test is a
much more expensive procedure than not stimulated cal-
citonin levels measurement and furthermore PG is not
commercially available in some countries.
By using a chemiluminescent assay, as performed in the
current study, calcitonin measurement takes no longer
than 15 min. This makes this technique suitable for an
intraoperatory application, as already performed in intra-
operative PTH monitoring in patients with primary hy-
perparathyroidism, inwhich the chemiluminescent assays
show to be the best method for measuring PTH (15),
requiring approximately 12 min and clearly indicating
to the surgeon before the end of surgery whether the
source of PTH has been removed. Furthermore, in com-
parison with ELISA, chemiluminescent assays show to
have advantages in handling a lower detection limit and
a higher sensitivity (16).
In conclusion, these results highlight that a decrease of
calcitonin serum concentrations greater than 50%30min
after surgery indicates that all the calcitonin-producing
tumor tissue has been removed. On the contrary, a calci-
tonin decrease lower than 50% seems to suggest an in-
complete surgery and, of consequence, a persistence of
disease. By a practical point of view, the intraoperative
calcitoninmonitoringmay reliably indicatewhetherMTC
patients had to be treated with a radical lymph node
dissection.
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